Search - tctmd.com

Displaying 61 - 80 of 85

Sort: Relevancy | Date

News Conference News TCT 2015

Updates to CoreValve Extreme Risk Study Encouraging

October 13, 2015

News Daily News

Survival Benefit of CoreValve in High-Risk Patients Persists at 2 Years

July 07, 2015

News Daily News

El Beneficio sobre la Supervivencia de CoreValve en Pacientes de Alto Riesgo se Mantiene a los 2 Años

July 07, 2015

Presentation

2-Year Outcomes in Patients Undergoing Surgery or Self-Expanding TAVR

Presenter: Michael J. Reardon

July 06, 2015

Presentation ACC 2015

A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis Deemed at Increased Risk for Surgery 2-Year Outcomes

Presenter: Michael J. Reardon

March 15, 2015

News Conference News ACC 2015

Follow-up TAVR Studies Reassure About Valve Durability, Outcomes

Todd Neale

March 15, 2015

Presentation TCT 2014

The Five Multislice CT Essentials for Optimal TAVR

Presenter: Alain G. Cribier, Michael J. Reardon, Steven J. Yakubov, Jonathon A. Leipsic

September 14, 2014

Presentation TCT 2014

The Five Echocardiographic Essentials for Optimal TAVR

Presenter: Alain G. Cribier, Michael J. Reardon, Steven J. Yakubov, Rebecca T. Hahn

September 14, 2014

Presentation TCT 2014

Multi-device Patient-Specific TAVR Now or in the Future?

Presenter: Alain G. Cribier, Michael J. Reardon, Steven J. Yakubov, Raj Makkar

September 14, 2014

Presentation TCT 2014

Lessons From the CHOICE Trial

Presenter: Alain G. Cribier, Michael J. Reardon, Steven J. Yakubov, Mohamed Abdel-Wahab

September 14, 2014

Presentation TCT 2014

Special Attributes and Disadvantages of the Balloon-Expandable TAVR Platform

Presenter: Alain G. Cribier, Michael J. Reardon, Steven J. Yakubov, John G. Webb

September 14, 2014

Presentation TCT 2014

Special Attributes and Disadvantages of the Self-Expanding TAVR Platform

Presenter: Alain G. Cribier, Michael J. Reardon, Steven J. Yakubov, Nicolo Piazza

September 14, 2014

Presentation TCT 2014

TAVR Alternative Access: Balancing Risks and Benefits of Subclavian, Direct Aortic, and Transapical Approaches

Presenter: Josep Rodés-Cabau, Mathew Williams, Azeem Latib, Michael J. Reardon

September 14, 2014

Presentation TVT 2014

Lessons Learned about Frailty and Comorbidities from the US CoreValve Trials

Presenter: Michael J. Reardon

June 07, 2014

Presentation TVT 2014

Direct Aortic is Clearly Superior to Transapical!

Presenter: Michael J. Reardon

June 07, 2014

Presentation TVT 2014

Direct Aortic TAVR: Indications, Optimal Technique, and Outcomes

Presenter: Michael J. Reardon

June 07, 2014

Presentation TVT 2014

Lotus - Status of the US Clinical Trial and Case Examples

Presenter: Ted E. Feldman, Michael J. Reardon

June 06, 2014

Presentation TVT 2014

The High-Risk Randomized Trial

Presenter: Michael J. Reardon

June 05, 2014

CME

Low-Risk Patients: The Changing Face of TAVR

CME

Advertisement

Updates to CoreValve Extreme Risk Study Encouraging

Survival Benefit of CoreValve in High-Risk Patients Persists at 2 Years

El Beneficio sobre la Supervivencia de CoreValve en Pacientes de Alto Riesgo se Mantiene a los 2 Años

2-Year Outcomes in Patients Undergoing Surgery or Self-Expanding TAVR

A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis Deemed at Increased Risk for Surgery 2-Year Outcomes

Follow-up TAVR Studies Reassure About Valve Durability, Outcomes

The Five Multislice CT Essentials for Optimal TAVR

The Five Echocardiographic Essentials for Optimal TAVR

Multi-device Patient-Specific TAVR Now or in the Future?

Lessons From the CHOICE Trial

Special Attributes and Disadvantages of the Balloon-Expandable TAVR Platform

Special Attributes and Disadvantages of the Self-Expanding TAVR Platform

TAVR Alternative Access: Balancing Risks and Benefits of Subclavian, Direct Aortic, and Transapical Approaches

Lessons Learned about Frailty and Comorbidities from the US CoreValve Trials

Direct Aortic is Clearly Superior to Transapical!

Direct Aortic TAVR: Indications, Optimal Technique, and Outcomes

Lotus - Status of the US Clinical Trial and Case Examples

The High-Risk Randomized Trial

Low-Risk Patients: The Changing Face of TAVR

Updates on TAVR in Low-Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content